chore: daily update 2026-08-09
This commit is contained in:
OpenWiki Bot
@@ -59,6 +59,8 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
|
||||
|
||||
- **Whitepaper: "Breaking the Bias" (2026, 16 pp)** — CelVivo's official vendor narrative on brain organoid long-term culture. Key data: ~110 day / 8 mm diameter brain organoid (Univ. Groningen, Trombetta-Lima); sc-RNA-seq 17,738 cells at Day 90 (Univ. Lausanne, Bagni); Day 30/45 dorsal forebrain comparison vs orbital shaker (Drexel, Qiang); hiPSC → cortical organoid + Omicron BA.5 (QIMR Berghofer, Stewart 2022). 4 patents: WO 2021/001472, WO 2021/245117, WO 2022/008292, WO 2022/144461. Full synthesis at [`/sources/literature-celvivo-brain-whitepaper-2026.md`](/sources/literature-celvivo-brain-whitepaper-2026.md).
|
||||
- **Bosnjakovic 2025 bioRxiv (PAH HepG2 3D spheroid, ClinoStar dynamic culture)** — 21-day maturation + 24h/96h BaP/BBF exposure; **4 metabolic markers (phenylalanine, TCA intermediates, GSH depletion, sphingolipid dysregulation) only appear in 3D, completely invisible in 2D**. Sales ammunition: "your 2D model is missing 100% of environmental toxicology early signals". Synthesis at [`/sources/literature-cel-bosnjakovic-2025-pah-deepread.md`](/sources/literature-cel-bosnjakovic-2025-pah-deepread.md).
|
||||
- **Miao 2025 Cell v2 (co-differentiation mesoderm + endoderm, vascularized lung/gut organoids, ClinoStar rotating culture)** — single 3D EB co-induction strategy yields **vHLPO with 7% ECs vs traditional HLPO 0%**, organ-specific endothelium + mesenchyme scRNA-seq validation, in-vivo functional integration with host circulation, FOXF1 mutation ACDMPV dual-pathology disease modeling. Product relevance: CelVivo ClinoStar rating 5 (co-differentiation depends on 3D EB self-organization in low-shear rotating culture — ClinoStar is the canonical hardware), HD-MEA rating 4, 3D bioprinting rating 3, patient-derived organoid drug screening rating 5. Synthesis at [`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`](/sources/literature-miao-2025-cell-vascularization-v2-deepread.md).
|
||||
- **Liu 2026 Nat Biomed Eng (shape-conformal porous framework for neural organoid e-phys, Rogers Lab)** — CelVivo ClinoStar rating 4 (organoid culture downstream of the shape-conformal framework; long-term maturation + functional readout is the canonical ClinoStar → HD-MEA workflow). Synthesis at [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md). See 3Brain evidence for the HD-MEA read side.
|
||||
- **Sales ammunition kit (CelVivo pricing + 8 Protocols + 5 app notes + 5 brand/whitepapers)** — Demo kit `10005-6` lists at €300 (Global Distributor Price, with special discount). 8 ClinoReactor Protocols cover prepare / media change / gardening / plate config / rotation-speed / alginate embed / VitroGel embed. 5 application notes cover HepG2/C3A liver, FTC-133 thyroid, NCI-H69V SCLC, TNBC, ClinoStar vs Orbital Shaker. Synthesis at [`/sources/sales-ammunition.md`](/sources/sales-ammunition.md).
|
||||
- **260528_CS vs OS app note (2026-07-17 deep read)** — ClinoStar vs Orbital Shaker shear-stress comparison for long-term 3D construct performance; ClinoStar has lower shear + long-term growth + better consistency. This is the **vs-competitor killer document** for "why not use an orbital shaker" customer questions.
|
||||
- **111_Planimetry app note (2026-07-17 deep read)** — Planimetry measurements of spheroids in ClinoReactor using FIJI (open-source). Standard answer for "how to quantify spheroids".
|
||||
@@ -66,6 +68,8 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
|
||||
### 3Brain evidence
|
||||
|
||||
- **Raji 2026 Mol Psychiatry (hMOs + 3Brain HD-MEA, 2026-07-27 deep read)** — WNT-modulated human midbrain organoids + 3Brain BioCAM DupleX + Accura-3D (4096 electrodes) + BrainWave 5. **TH+ 58% at 12 weeks** (vs 2D 18%, 3D static 32%). DA release 76 pg/mL (vs 2D 12, 3D static 28). α-synuclein PFF → DA neurons -35% / TH -40% / DA release -45% — establishes the **PD drug screening platform**. Shear-stress 15x lower than orbital shaking (0.13 dyn/cm² vs 2.03 dyn/cm²). Synthesis at [`/sources/literature-raji-2026-deepread.md`](/sources/literature-raji-2026-deepread.md).
|
||||
- **Liu 2026 Nat Biomed Eng (shape-conformal porous framework, full-coverage neural organoid e-phys, Rogers Lab)** — HD-MEA rating 5: **3000-8000 channels per organoid vs traditional MEA 200-1000 (10-50× improvement), >90% surface coverage vs 5-15%, weeks-long stable recording + bi-directional electrical + optogenetic stimulation, epilepsy + AD disease modeling**. The framework is the **direct next-generation design reference** for 3Brain's current 4096-electrode Accura-3D; Robin should sell Accura-3D as the existing best-in-class and Liu 2026 as the forward-looking 3D-coverage direction. Synthesis at [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md). Tracks as `liu-2026-hd-mea-roadmap-implication` commitment (verify with 3Brain whether flexible-electronics / shape-conformal framework is on their roadmap).
|
||||
- **Sharma 2026 Cell Stem Cell (vascularized retinal organoids, RGC survival)** — HD-MEA rating 4: paper uses 60-channel MCS MEA2100-Lite; 3Brain HD-MEA is same-generation HD technology, technical route is transferable. The W31 ON/OFF/ON-OFF light-response recording paradigm is the kind of long-duration, multi-class recording where HD spatial resolution matters most. CelVivo ClinoStar rating 3 (vascular network regresses in static culture → ClinoStar low-shear route candidate). W18 RGC yield **18.2% vs ctrl-RO 1.21% (15× improvement)** through C3 endothelial monolayer integration. Synthesis at [`/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md`](/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md).
|
||||
- **3Brain Sample Holder Set / PressNet (UK GB2624872)** — Mechanical net-press device for CorePlate 1W/6W; load force 250–1250 µN. Recorded 2026-07-07 (untracked in vault). Carryover evidence in [`/sources/git-repo.md`](/sources/git-repo.md) Notable entities.
|
||||
- **3Brain end-customer dossiers** — 11+ dossiers under `03-Resources/End-Customers/` covering 神经所 (上海), 北京大学, 北京天坛医院, 浙大一附院, 中科院昆明动物所, 西南医科大学, 贵州医科大学, plus TCM accounts at 云南中医药大学 and 天津创新中药. Listed in [`/sources/git-repo.md`](/sources/git-repo.md) Notable entities.
|
||||
- **Vendor-channel strand (Tavily 2026-07-30 → 2026-08-03)** — 3Brain's official website + LinkedIn (booth 412 at ISSCR 2026; booth 4 at ELRIG Drug Discovery; Utrecht Summer School "Human Brain Models" course 2026-07-29). Tracks in `/commitments.md` as `3brain-coreplate-2026-conference-positioning` (verify which conference posts are current and pull application notes).
|
||||
@@ -73,6 +77,8 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
|
||||
## Cross-vendor workflow links
|
||||
|
||||
- **CelVivo + 3Brain joint workflow** (from Raji 2026): hMOs are cultured in a **bioreactor** (CelVivo-class, low-shear rotating-wall) for 12 weeks; transplanted to **3Brain Accura-3D** (4096-electrode HD-MEA chip) for 24h spike-train recording via BrainWave 5. Two pieces of hardware from two vendors compose the **PD drug screening platform** Robin sells.
|
||||
- **CelVivo + 3Brain next-gen workflow** (from Liu 2026): the shape-conformal porous framework (Rogers Lab, next-gen HD-MEA design) records 3000-8000 channels per organoid vs current 4096 — **forward-looking direction** for the CelVivo → 3Brain pipeline. Track in `/commitments.md` as `liu-2026-hd-mea-roadmap-implication`.
|
||||
- **CelVivo + 3Brain vascularized organoid workflow** (from Miao 2025 v2 + Sharma 2026): vHLPO and vRO use single 3D EB co-induction (mesoderm+endoderm) or C3 endothelial monolayer integration. The vascular-like networks regress in static culture — **CelVivo ClinoStar low-shear rotating culture is the candidate route to extend maturation**. Functional readout remains 3Brain HD-MEA territory (60-channel MEA in Sharma; future HD-MEA for vascularized organoids).
|
||||
- **CelVivo + TheWell Bioscience xeno-free workflow** (Tavily 2026-07-21/23/25): TheWell's hydrogel-media workflow pages position **ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion**. Tracks in `/commitments.md` as `celvivo-clinoreactor-thewell-bioscience-xeno-free` (verify whether sanctioned co-marketing).
|
||||
- **CelVivo + Femtobiomed** (small but complementary): Femtobiomed CellShot / CellPick / TriArm for hiPSC electroporation upstream of CelVivo 3D culture.
|
||||
|
||||
@@ -101,6 +107,9 @@ The state diagram shows the canonical CelVivo → 3Brain workflow: 3D suspension
|
||||
| What is ClinoReactor's pricing? | [`/sources/sales-ammunition.md`](/sources/sales-ammunition.md) |
|
||||
| What does the CelVivo brain organoid whitepaper actually say? | [`/sources/literature-celvivo-brain-whitepaper-2026.md`](/sources/literature-celvivo-brain-whitepaper-2026.md) |
|
||||
| What is Raji 2026's PD drug screening story? | [`/sources/literature-raji-2026-deepread.md`](/sources/literature-raji-2026-deepread.md) |
|
||||
| What is Miao 2025's vascularized lung/gut organoid story? | [`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`](/sources/literature-miao-2025-cell-vascularization-v2-deepread.md) |
|
||||
| What is Liu 2026's shape-conformal neural organoid e-phys story? | [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md) |
|
||||
| What is Sharma 2026's vascularized retinal organoid RGC story? | [`/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md`](/sources/literature-sharma-2026-cell-stem-cell-vascularized-retinal-organoid-rgc-deepread.md) |
|
||||
| What distributors am I actually working with? | [`/sources/agents.md`](/sources/agents.md) |
|
||||
| Which Chinese dealers carry our brand? | [`/sources/distributors-china-2026.md`](/sources/distributors-china-2026.md) |
|
||||
| What regulatory shifts affect our Chinese pharma deals? | [`/commitments.md`](/commitments.md) China CDE / Order No. 818 / China CGT items |
|
||||
|
||||
Reference in New Issue
Block a user